Medtronic plc

NYSE:MDT

Medical - Devices

Healthcare
$100.72 +0.96%

+$0.75 today

Market cap
$128.84B
Beta
0.60
P/E (TTM)
21.1
EPS (TTM)
$3.74
Dividend yield
3.60%
52W Low $73.31High $106.33

Volume 6.47M

Average 11.36M

MDT Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Medtronic plcNYSE: MDT

Capital Expenditures · Q1 FY2027 · quarter ended Jul 2026

Capital expenditures dips below year-ago levels

Q1 FY2027 capital expenditures of $503M (cash outflow) fell 0.2% year over year, behind the +3.3% change in trailing-twelve-month capital expenditures. Sequentially, it rose 3.1% from the prior quarter. Over 3 fiscal years it compounded at +9.3% a year.

Context

  • Capital expenditures amounted to 5.2% of revenue in FY2026, down 0.3 pp from a year earlier.
  • Capital expenditures grew in size in 3 of the last 3 fiscal years.
  • FY2026 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -0.2% toward the trailing-twelve-month pace of +3.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJul 2026
-$503M+3.1% QoQ
Last fiscal yearApr 2026
-$1.9B+2.4% YoY
LTMJul 2026
-$1.9B+3.3% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.2%——
1 year+2.4%——
3-year CAGR+9.3%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2026
(1.9B) USD
Year-over-year change
-2.4%

Capital Expenditures vs competitors

How MDT compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3.3% is the 7th highest of 9, against a peer median of +54.3%.
  • Capital expenditures amounts to 5.1% of revenue for MDT, versus a peer median of 4.2%.
MDT Competitors
Capital Expenditures for MDT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$1.9B USD+3.3%+9.3%5.1%
BSXBoston Scientific CorporationLTM Jun 2026$904M USD-7.2%+12.7%4.3%
SYKStryker CorporationLTM Jun 2026$823M USD+10.9%+9.0%3.2%
PHGKoninklijke Philips N.V.LTM Jun 2026€382.2M EUR+76.2%-16.8%2.2%
EWEdwards Lifesciences CorporationLTM Jun 2026$286.7M USD+53.3%-0.6%4.4%
LIVNLivaNova PLCLTM Sep 2026$108.84M USD+83.8%+45.2%7.2%
ZBHZimmer Biomet Holdings, Inc.LTM Jun 2026$86.8M USD+136.3%+1.0%1.0%
PENPenumbra, Inc.LTM Jun 2026$61.9M USD+55.3%+48.9%4.1%
AVRAnteris Technologies Global Corp.LTM Mar 2026$1.69M USD-6.5%+5.5%91.5%
Peer median (excluding MDT) —+54.3%+7.2%4.2%

Competitors are the stored peer set for MDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Apr 2026
Net Income5.06B3.78B3.68B4.69B4.84B
Depreciation & Amortization2.71B2.7B2.65B2.86B2.96B
Deferred Income Tax(604M)(226M)(508M)(316M)51M
Stock-Based Compensation359M355M393M429M457M
Change in Working Capital(889M)(967M)(484M)(1.05B)(1.42B)
Accounts Receivables(477M)(576M)(391M)(433M)(200M)
Inventory(560M)(939M)(139M)(292M)(404M)
Accounts Payables213M696M391M209M46M
Other Working Capital(65M)(148M)(345M)(538M)(865M)
Other Non-Cash Items711M396M1.06B433M450M
Operating Cash Flow7.35B6.04B6.79B7.04B7.33B
Capital Expenditures(1.37B)(1.46B)(1.59B)(1.86B)(1.9B)
Acquisitions (Net)(91M)(1.87B)(211M)(98M)(406M)
Purchases of Investments(9.88B)(7.51B)(7.75B)(8.23B)(8.73B)
Sales of Investments9.69B7.34B7.44B8.5B8.11B
Other Investing Activities(10M)4M(261M)(249M)(4M)
Investing Cash Flow(1.66B)(3.49B)(2.37B)(1.94B)(2.93B)
Debt Repayment(1M)(598M)1.07B2.14B(1.17B)
Common Stock Issued429M308M284M508M516M
Common Stock Repurchased(2.54B)(645M)(2.14B)(3.24B)(1.04B)
Dividends Paid(3.38B)(3.62B)(3.67B)(3.59B)(3.64B)
Other Financing Activities163M(101M)(3M)(184M)582M
Financing Cash Flow(5.34B)(4.96B)(4.45B)(4.36B)(4.75B)
Effect of Forex Changes(230M)243M(230M)188M85M
Net Change in Cash121M(2.17B)(259M)934M(269M)
Free Cash Flow5.98B4.58B5.2B5.19B5.43B

Medtronic plc

NYSE:MDT

Intrinsic Alpha fair value

Locked

Current Price

$100.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.